Biotech

All Articles

Zephyrm looks for Hong Kong IPO to finance period 3 cell therapy tests

.Zephyrm Bioscience is actually gusting towards the Hong Kong stock market, submission (PDF) for an ...

Frazier Lifestyle Sciences gets $630M for small, mid-cap biotechs

.Frazier Lifespan Sciences has sourced a further $630 thousand for its fund focused on little and mi...

GigaGen garners approximately $135M BARDA money to beat botulism

.Antitoxin connoisseur GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its tech to...

GPCR company Septerna files for IPO on strength of preclinical records

.Septerna will figure out how a biotech without "any kind of relevant medical data" fares in the ove...

Kurma shuts initially $154M haul for most significant biotech fund as yet

.International VC agency Kurma Allies has actually revealed its own newest biotech fund, along with ...

Prothena promotes one exec while one more leaves behind-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings and...

Editas cashes in on Tip Cas9 licensing civil rights for $57M

.Against the background of a Cas9 patent fight that refuses to perish, Editas Medicine is actually m...

Ultragenyx adjusts genetics treatment application to dial up effectiveness

.A minority of clients taking Ultragenyx Drug's Wilson disease genetics treatment UX701 have gone ov...

Biopharma discharge rate stabilizes in Q3: Ferocious Biotech analysis

.As summer season heat energy looks to cool winds, really hopes that this year would carry extensive...

J &amp J goes down phase 2 dengue candidate in most recent change coming from vaccinations

.Johnson &amp Johnson's deprioritization of its contagious condition pipeline has declared another t...